ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $248,000 | -25.8% | 253,061 | +5.2% | 0.00% | – |
| Q2 2023 | $334,269 | +14.2% | 240,481 | +30.6% | 0.00% | – |
| Q1 2023 | $292,694 | -50.5% | 184,084 | +93.8% | 0.00% | – |
| Q4 2022 | $591,685 | +975.8% | 94,974 | +1042.3% | 0.00% | – |
| Q3 2022 | $55,000 | 0.0% | 8,314 | -4.1% | 0.00% | – |
| Q2 2022 | $55,000 | +77.4% | 8,669 | +30.0% | 0.00% | – |
| Q1 2022 | $31,000 | -99.1% | 6,666 | -94.8% | 0.00% | – |
| Q4 2020 | $3,307,000 | -30.1% | 127,199 | -0.0% | 0.00% | – |
| Q3 2020 | $4,728,000 | -33.4% | 127,200 | -8.1% | 0.00% | -100.0% |
| Q2 2020 | $7,103,000 | +8.6% | 138,440 | -33.3% | 0.00% | 0.0% |
| Q1 2020 | $6,543,000 | -46.7% | 207,529 | +0.8% | 0.00% | 0.0% |
| Q4 2019 | $12,275,000 | +50.7% | 205,864 | -7.4% | 0.00% | 0.0% |
| Q3 2019 | $8,148,000 | -35.8% | 222,253 | -18.5% | 0.00% | 0.0% |
| Q2 2019 | $12,682,000 | -45.5% | 272,629 | -52.9% | 0.00% | -66.7% |
| Q1 2019 | $23,256,000 | -31.6% | 579,236 | -21.6% | 0.00% | -40.0% |
| Q4 2018 | $34,007,000 | +49.1% | 739,289 | +43.8% | 0.01% | +66.7% |
| Q3 2018 | $22,810,000 | -36.9% | 514,084 | -44.3% | 0.00% | -25.0% |
| Q2 2018 | $36,172,000 | -71.0% | 922,979 | -46.5% | 0.00% | -73.3% |
| Q1 2018 | $124,781,000 | +51.0% | 1,725,169 | +37.5% | 0.02% | +50.0% |
| Q4 2017 | $82,628,000 | +22.8% | 1,254,988 | -6.5% | 0.01% | +25.0% |
| Q3 2017 | $67,306,000 | +8.6% | 1,342,888 | +0.3% | 0.01% | 0.0% |
| Q2 2017 | $61,950,000 | +34.1% | 1,338,588 | +2.3% | 0.01% | +33.3% |
| Q1 2017 | $46,206,000 | +381.8% | 1,308,588 | +70.8% | 0.01% | +500.0% |
| Q4 2016 | $9,590,000 | -9.6% | 766,009 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $10,609,000 | +0.5% | 766,009 | -28.3% | 0.00% | 0.0% |
| Q2 2016 | $10,561,000 | -46.9% | 1,068,950 | -9.1% | 0.00% | -66.7% |
| Q1 2016 | $19,882,000 | -52.5% | 1,175,750 | -37.5% | 0.00% | -50.0% |
| Q4 2015 | $41,854,000 | -30.0% | 1,880,250 | -25.9% | 0.01% | -33.3% |
| Q3 2015 | $59,831,000 | -66.9% | 2,536,271 | +14.8% | 0.01% | -60.9% |
| Q2 2015 | $180,627,000 | -10.8% | 2,209,232 | +1.0% | 0.02% | -11.5% |
| Q1 2015 | $202,454,000 | +257.3% | 2,186,332 | +56.0% | 0.03% | +271.4% |
| Q4 2014 | $56,668,000 | +2664.3% | 1,401,274 | +1572.2% | 0.01% | – |
| Q3 2014 | $2,050,000 | +54.5% | 83,800 | 0.0% | 0.00% | – |
| Q2 2014 | $1,327,000 | -1.5% | 83,800 | -5.9% | 0.00% | – |
| Q1 2014 | $1,347,000 | +10.0% | 89,100 | 0.0% | 0.00% | – |
| Q4 2013 | $1,224,000 | -86.8% | 89,100 | -81.9% | 0.00% | -100.0% |
| Q3 2013 | $9,298,000 | – | 493,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |